Full text is available at the source.
Synergistic CRISPR/Cas12a-Nanozyme System for Iontronic Sensing of Site-Specific Septin9 Methylation
Combined CRISPR and Nanozyme System for Ion-Based Detection of Specific DNA Methylation in Septin9
AI simplified
Abstract
The detection limit of the proposed method for septin9-mC is 34.0 aM, with a linear range from 100 aM to 10 nM.
- Methylated septin9 (septin9-mC) is a validated biomarker for colorectal cancer screening.
- Conventional detection methods are limited by pretreatment requirements, DNA degradation, and low performance in scarce samples.
- The proposed iontronic sensing platform utilizes a combination of methylation-sensitive restriction enzymes, CRISPR/Cas12a, and nanozymes for improved specificity and sensitivity.
- The method distinguishes colorectal cancer cells from human colonic epithelial cells effectively.
- It also differentiates colorectal cancer patients from healthy individuals in real sample analysis.
AI simplified